维生素B1联合帕罗西汀治疗卒中后抑郁症的临床疗效

Clinical Effect of Combination of Paroxeting and Vitamin B1 in the Treatment of Post-stroke Depression

目的:探讨维生素B1与帕罗西汀联合治疗卒中后抑郁症(PSD)的临床疗效。方法:PSD患者60例随机分为联合组和对照组各30例。2组均给予帕罗西汀治疗,联合组在此基础上给予维生素B1治疗,疗程8周。于治疗前及治疗开始后2、4、8周时分别使用汉密尔顿抑郁量表(HAMD)、抑郁自评量表(SDS)评估疗效,采用不良反应量表(TESS)评估不良反应。结果:2组治疗第2周末疗效差异无统计学意义(P>0.05);第4、8周末联合组的HAMD、SDS评分较对照组下降(P<0.05),疗效优于对照组(P<0.05)。TESS评分差异无统计学意义(P>0.05)。结论:维生素B1联合帕罗西汀治疗PSD较单用帕罗西汀疗效显著,且不会增加不良反应。

Objective： To explore the clinical effect of combination of vitamin B1 and paroxeting in the treatment of post-stroke depression（PSD）. Methods： Sixty PSD patients were randomly divided into combination group and control group, with 30 cases in each group. Both the groups were given paroxiting, and the combination group was given additional vitamin B1 for 8 weeks. The clinical effect was measured by Hamilton Depression Scale（HAMD）and Self-rating Depression Scale（SDS） before the treatment and at the ends of 2nd, 4th, 8th week of the treatment.Moreover, the treatment emergent symptom scale（TESS） was used to observe the side effects. Results： At the end of the 2nd week, there was no significantly difference in the clinical effect in the two groups（P〉0.05）. At the end of4 th and 8th week treatment, scores of the HAMD and SDS were decreased more significantly in the combination group than those in the control group（P〈0.05）, and the clinical effect was better in the combination group（P〈0.05）.There was no significantly difference in the TESS scores in the 2 groups（P〉0.05）. Conclusion： Paroxeting combined with vitamin B1 shows better clinical efficacy than single paroxeting in the treatment of PSD.